VISTA expressed in tumour cells regulates T cell function.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
04
05
2018
accepted:
02
10
2018
revised:
24
09
2018
pubmed:
2
11
2018
medline:
19
9
2019
entrez:
2
11
2018
Statut:
ppublish
Résumé
V-domain Ig suppressor of T cell activation (VISTA) is a novel inhibitory immune-checkpoint protein. VISTA expression on tumour cells and the associated regulatory mechanisms remain unclear. We investigated VISTA expression and function in tumour cells, and evaluated its mechanism and activity. VISTA in tumour cells was assessed by tissue microarray analysis, immunohistochemical staining and western blot. A series of in vitro assays were used to determine the function of tumour-expressed VISTA. In vivo efficacy was evaluated in syngeneic models. VISTA was highly expressed in human ovarian and endometrial cancers. Upregulation of VISTA in endometrial cancer was related to the methylation status of the VISTA promoter. VISTA in tumour cells suppressed T cell proliferation and cytokine production in vitro, and decreased the tumour-infiltrating CD8+ T cells in vivo. Anti-VISTA antibody prolonged the survival of tumour-bearing mice. This is the first demonstration that VISTA is highly expressed in human ovarian and endometrial cancer cells, and that anti-VISTA antibody treatment significantly prolongs the survival of mice bearing tumours expressing high levels of VISTA. The data suggest that VISTA is a novel immunosuppressive factor within the tumour microenvironment, as well as a new target for cancer immunotherapy.
Sections du résumé
BACKGROUND
V-domain Ig suppressor of T cell activation (VISTA) is a novel inhibitory immune-checkpoint protein. VISTA expression on tumour cells and the associated regulatory mechanisms remain unclear. We investigated VISTA expression and function in tumour cells, and evaluated its mechanism and activity.
METHODS
VISTA in tumour cells was assessed by tissue microarray analysis, immunohistochemical staining and western blot. A series of in vitro assays were used to determine the function of tumour-expressed VISTA. In vivo efficacy was evaluated in syngeneic models.
RESULTS
VISTA was highly expressed in human ovarian and endometrial cancers. Upregulation of VISTA in endometrial cancer was related to the methylation status of the VISTA promoter. VISTA in tumour cells suppressed T cell proliferation and cytokine production in vitro, and decreased the tumour-infiltrating CD8+ T cells in vivo. Anti-VISTA antibody prolonged the survival of tumour-bearing mice.
CONCLUSIONS
This is the first demonstration that VISTA is highly expressed in human ovarian and endometrial cancer cells, and that anti-VISTA antibody treatment significantly prolongs the survival of mice bearing tumours expressing high levels of VISTA. The data suggest that VISTA is a novel immunosuppressive factor within the tumour microenvironment, as well as a new target for cancer immunotherapy.
Identifiants
pubmed: 30382166
doi: 10.1038/s41416-018-0313-5
pii: 10.1038/s41416-018-0313-5
pmc: PMC6325144
doi:
Substances chimiques
B7 Antigens
0
VSIR protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
115-127Références
Annu Rev Immunol. 2008;26:677-704
pubmed: 18173375
Clin Cancer Res. 2018 Apr 1;24(7):1562-1573
pubmed: 29203588
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
pubmed: 19474385
Semin Oncol. 2007 Apr;34(2 Suppl 2):S1-15
pubmed: 17512352
Cancer Res. 2014 Apr 1;74(7):1924-32
pubmed: 24691993
Stem Cells. 2010 Jan;28(1):164-73
pubmed: 19911426
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Nat Med. 2017 May;23(5):551-555
pubmed: 28346412
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5
pubmed: 17360651
J Clin Oncol. 2017 Aug 1;35(22):2535-2541
pubmed: 28489510
J Clin Oncol. 2015 Dec 1;33(34):4015-22
pubmed: 26351349
Cancer Immunol Res. 2014 Jun;2(6):510-7
pubmed: 24894088
J Immunol Res. 2015;2015:191832
pubmed: 26236750
J Invest Dermatol. 2017 Jun;137(6):1384-1386
pubmed: 28104378
Int J Mol Sci. 2013 Jun 27;14(7):13482-96
pubmed: 23807506
Oral Oncol. 2016 Jun;57:54-60
pubmed: 27208845
Nat Rev Clin Oncol. 2016 Feb;13(2):71-2
pubmed: 26718108
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Carcinogenesis. 2000 Apr;21(4):585-91
pubmed: 10753190
J Clin Oncol. 2015 Jun 10;33(17):1974-82
pubmed: 25605845
Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14846-51
pubmed: 25267631
J Clin Oncol. 2011 Mar 1;29(7):925-33
pubmed: 21079136
J Immunol. 2015 Jun 1;194(11):5294-304
pubmed: 25917101
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Nat Rev Immunol. 2009 Mar;9(3):162-74
pubmed: 19197294
J Exp Med. 2011 Mar 14;208(3):577-92
pubmed: 21383057
Cell Physiol Biochem. 2017;43(5):1893-1906
pubmed: 29055949
Nat Rev Immunol. 2008 Jun;8(6):467-77
pubmed: 18500231
ESMO Open. 2016 Aug 26;1(4):e000083
pubmed: 27843633
Methods. 2002 Jun;27(2):179-83
pubmed: 12095278
Science. 2015 Jul 31;349(6247):1261669
pubmed: 26228159
Cancer Sci. 2010 Nov;101(11):2368-74
pubmed: 20666777
FASEB J. 2012 Oct;26(10):3957-68
pubmed: 22751012
Cancer Immunol Res. 2015 Dec;3(12):1308-15
pubmed: 26546452
J Clin Oncol. 2015 Dec 1;33(34):3987-9
pubmed: 26503205
J Clin Invest. 2014 May;124(5):1966-75
pubmed: 24743150
Clin Cancer Res. 2013 Mar 1;19(5):1021-34
pubmed: 23460533
Cancer Res. 2014 Apr 1;74(7):1933-44
pubmed: 24691994
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173
Sci Rep. 2016 Oct 10;6:34860
pubmed: 27721458
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
BMC Bioinformatics. 2011 May 27;12:213
pubmed: 21619611
Proc Natl Acad Sci U S A. 2015 May 26;112(21):6682-7
pubmed: 25964334
Nat Rev Immunol. 2012 Mar 22;12(4):253-68
pubmed: 22437938